Mediclinic International plc (Incorporated in England and Wales) Company Number: 08338604 LSE Share Code: MDC JSE Share Code: MEI NSX Share Code: MEP ISIN: GB00B8HX8Z88 LEI: 2138002S5BSBIZTD5I60 ('Mediclinic', or the 'Company', or the 'Group')

6 December 2022

### NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1.	Details of persons discharging managerial responsibilities ('PDMR') / persons closely associated with them ('PCA')		
a)	Name	Koert Pretorius	
2.	Reason for the notification		
a)	Position / status	Group Chief Operating Officer – Mediclinic International plc	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Mediclinic International plc	
b)	LEI	2138002S5BSBIZTD5I60	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary shares	
	Identification Code	GB00B8HX8Z88	
b)	Nature of the transaction	Sale of shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		ZAR 104.21	75 000
d)	Aggregated information		
	Aggregated volume	75 000	
	Price	ZAR 104.21 per share	

e)	Date of the transaction	5 December 2022
f)	Place of the transaction	Johannesburg Stock Exchange

# ABOUT MEDICLINIC INTERNATIONAL PLC

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 30 September 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, three mental health facilities, 21 day case clinics and 23 outpatient clinics. Hirslanden operated 17 hospitals and five day case clinics in Switzerland with around 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, three mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract Mediclinic Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ('LSE') in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% (2022: 29.9%) interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

## **CONTACT INFORMATION**

### Investor queries

James Arnold, Head of Investor Relations, Mediclinic International plc +44 (0)20 3786 8181 ir@mediclinic.com

### Media queries

FTI Consulting Ben Atwell/Ciara Martin – UK +44 (0)20 3727 1000 Sherryn Schooling – South Africa +27 (0)21 487 9000

Registered address: 6<sup>th</sup> Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom Website: <u>www.mediclinic.com</u> Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd) NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd